EvaluatePharma researchers totted up sales for the last 5 years' worth of analysts' blockbuster picks--and found plenty of bad bets.
Chalk up another big win for Hal Barron and his R&D team extraordinaire at Genentech. The FDA today approved a new indication for Roche's ($RHHBY) cancer drug Avastin.
Roche tightened its lock on the breast cancer treatment market, and its expectations for many more billions of dollars in annual revenue, when an EU panel gave thumbs up for approval of Perjeta.
Roche moved a step closer to adding another gem to its crown as the leading provider of therapies against a form of breast cancer. European officials backed approval of the Swiss drug giant's Perjeta (pertuzumab) for use as part of a combo attack on HER2-positive breast cancers.
Once again, Roche's ($RHHBY) quarterly results are a snapshot of Big Pharma hopes and travails. The Swiss drugmaker pulled off a 4% sales increase to 11.27 billion Swiss francs ($12.1 billion), with help from targeted cancer drugs and diagnostics. Oncology, of course, is one of the industry's most fertile fields, especially for drugs matched to patients with particular genetic quirks.
Investigators behind the big T-DM1 breast cancer program took the lid off the last big data box from its pivotal study this morning, revealing that the armed antibody delivered a 32% reduction in the risk of death among patients in the pivotal Phase III study when compared to the standard-of-care arm.
New breast cancer therapies will earn blockbuster revenue in the years to come. But don't expect these new drugs to dramatically change the life expectancy of women diagnosed with an advanced case.
The positive news keeps rolling in for the Roche ( $RHHBY ) drug Perjeta , even after it got approved this month by the FDA for HER2-positive disease. The company today said another study found people...
The FDA approved Roche's new treatment for HER2-positive disease, pertuzumab, now dubbed Perjeta.
Roche's Genentech subsidiary announced last night that the FDA had handed out an approval for pertuzumab, setting the stage for a new combo attack on HER2-positive cases.